Latest Immunosuppressants Stories
-33% rate of DAS28-CRP remission or low disease activity reported in Phase 2a cohort- MONROVIA, Calif., Jan. 29, 2015 /PRNewswire/ -- Xencor, Inc.
US Submission Designed to Support Conversion From Accelerated to Full FDA Approval and Expansion of Current Approved Indication THOUSAND OAKS, Calif.
LONDON, January 22, 2015 /PRNewswire/ -- Report Details Treating Crohn's disease and ulcerative colitis - how to find R&D trends, opportunities and revenue
- Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis EAST HANOVER, N.J., Jan.
-- First biosimilar from Samsung Bioepis to advance to EMA regulatory review -- INCHEON, South Korea, Jan.
HORSHOLM, Denmark, Jan. 14, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today confirmed that the U.S.
HORSHOLM, Denmark, Jan. 13, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today confirmed that it has received notice from the U.S.
HORSHOLM, Denmark, Dec. 19, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today issued the following statement regarding an order issued by the U.S.
ReportsandReports.com adds latest reports on Adalimumab Industry for Global and China Markets to its store. DALLAS, Dec.
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.
- In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.